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Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world, particularly in Southeast Asia and in
Sub-Saharan Africa (Linsell and Higginson, 1976; Beasley, 1982).
In Taiwan, it ranked the first in cancer mortality. The disease is
known to be closely associated with chronic hepatitis B or C viral
infection (Beasley, 1982; Chen, 1987, Chen et al, 1990), or expo-
sure to a-toxin B1 and environmental factors (Sheu et al, 1992).
Nevertheless, the molecular mechanism still needs to be clarified.
The genesis of human cancers is a multistep process reflecting
cumulative genetic alterations that include activation of oncogenes
or inactivation of tumour suppressor genes (Sheu et al, 1992;
Weissenbach et al, 1992). Loss of heterozygosity (LOH) in poly-
morphic markers in a chromosomal fragment is known to be
indicative of the presence of putative tumour suppressor genes
(Yeh et al, 1994, 1996; Kuroki et al, 1995a).
The recently identified short tandem repeat, the microsatellite,
which exhibits length polymorphism is widely and evenly distrib-
uted throughout the whole genome (Weissenbach et al, 1992).
These microsatellite markers have been used for primary gene
mapping and linkage analysis (Weissenbach et al, 1992).
Polymerase chain reaction (PCR) amplification of these sequences
allows rapid assessment of LOH and greatly simplifies the detec-
tion of LOH (Yeh et al, 1994, 1996; Kuroki et al, 1995a, 1995b).
Studies based on somatic LOH as a means of identifying critical
loci have already led to the discovery of several important tumour
suppressor genes, including the retinoblastoma (Rb), BRCA1,
BRCA2 and DPC4 genes (Kamb et al, 1994; Miki et al, 1994;
Linardopoulos et al, 1995; Wooster et al, 1995; Hahn et al, 1996).
Identification of subtle genetic changes indicative of microsatel-
lite instability can be obtained through the analysis of mobility
change of tumour DNA in electrophoresis (Peinado et al, 1992;
Ionov et al, 1993). Microsatellite instability has been reported in a
variety of human cancers, including colorectal carcinomas, but not
in adjacent normal tissues from the same individual (Peinado et al,
1992; Gonzalez-Zulueta et al, 1993; Han et al, 1993; Ionov et al,
1993; Peltomaki et al, 1993; Risinger et al, 1993; Thibodeau et al,
1993; Loeb, 1994; Merlo et al, 1994). In hereditary non-polyposis
colorectal carcinoma (HNPCC), this microsatellite instability is
apparently due to inherited and somatic mutations in mismatch
repair genes (Loeb, 1994). Mutations of these microsatellite insta-
bility genes may be an important mechanism in tumorigenesis.
By using restriction fragment length polymorphism (RFLP) and
microsatellite analysis, previous reports have demonstrated that
allelic losses on chromosomes 1p, 4q, 5q, 8p, 8q, 11p, 13q, 16q
and 17p are frequently found in HCC (Nose et al, 1993; Takahashi
et al, 1993; Fujimoto et al, 1994; Fujiwara et al, 1994; Yeh et al,
1994, 1996; Kuroki et al, 1995a, 1995b; Yumoto et al, 1995; Nagai
et al, 1997). These observations implicated that loss, or alterations,
of a number of tumour suppressor genes in these loci might play an
important role in the development of HCC. However, conflicting
results regarding the frequency and site of chromosome loss have
been shown in these studies. In the present study we used a total of
231 markers, representing 1–22 and X chromosomes to examine
systematically the LOH frequency in 30 cases of HCC. At the
same time, microsatellite instability was analysed. We hoped to
determine the specific sites for the putative tumour suppressor
genes in HCC. Meanwhile, the correlation with clinical parameters
was also studied.
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Summary Elucidation of the basic genetic changes of human hepatocellular carcinoma is important for the understanding and treatment of
this cancer. We used microsatellite polymorphism markers to study 30 cases of hepatocellular carcinoma (34 tumours) on all human
chromosomes. DNA from 34 pairs of hepatocellular carcinomas and corresponding non-tumour parts was prepared. Loss of heterozygosity
(LOH) and microsatellite instability on 23 chromosomes were investigated by 231 sets of microsatellite markers. More than 20% LOH was
shown for loci on 16q (47.1%), 13q (32.4%), 17p (32.4%), 5q (26.5%), 11p (23.5%) and 9p (20.6%). The commonly affected regions were
mapped to 16q12.1, 16q12.2, 16q24, 13q12.1–32, 17p13, 5q32, 5q34, 5q3, 11p15, 11q23–24 and 9p21. Hepatitis B virus carriers had a
significantly higher frequency of LOH on chromosomes 5q, 11p and 16q. Furthermore, larger tumour size tended to have higher frequency of
LOH at D16S409 locus (16q12.1). Microsatellte instability was only found in 12 of 231 markers and the frequency is very low. These data
suggest that the chromosomes 16q, 13q, 17p, 5q, 11p and 9p might participate in hepatocarcinogenesis. However, microsatellite instability
might play little role in the development of this cancer in Taiwan.
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MATERIALS AND METHODS
Patients
Primary HCC tissues and their corresponding non-neoplastic liver
tissues were obtained from 30 HCC patients receiving surgical
resection in National Taiwan University. The diagnosis of HCC
was confirmed by histology. Both tumour and non-tumour parts
were frozen immediately after surgery and stored at 21358C until
use. A total of 30 HCC patients were included in this study (Table
1). One patient (case 29) received two operations due to primary
and recurrent HCCs, and there were two tumours in each opera-
tion. Another patient (case 30) had two small tumours. Therefore,
a total of 34 tumours were studied. The tumour size was less than
3 cm in 14 tumours, between 3 and 5 cm in 13 tumours, and larger
than 5 cm in the remaining seven tumours. Twenty-one patients
were male and nine were female. The age ranged from 29 to 67
years. Twenty were positive and ten were negative for hepatitis B
surface antigen (HBsAg). Hepatitis C virus antibody (anti-HCV)
was positive in two of the 20 patients who were positive for
HBsAg. However, in the ten patients negative for HBsAg, nine
were positive and only one was negative for anti-HCV.
DNA isolation
Genomic DNAs were extracted from the tumour and non-tumour
liver tissues using methods described previously (Sheu et al, 1992).
Microsatellite polymorphism analysis
All these samples, including tumour and non-tumour parts, were
systematically studied by using the microsatellite markers (from
chromosomes 1–22 and X chromosome). These markers were
selected at a distance of every 10–20 cM according to
Weissenbach (Weissenbach et al, 1992) (Table 2). The primers
specific for these markers are commercially available (Research
Genetics, Huntsville, AL, USA) (Weissenbach et al, 1992). A total
of 231 microsatellite markers were used. Each marker was ampli-
fied by PCR in 25-ml volumes of a mixture containing 25 ng of
genomic DNA template, 5 pmol of each primer, 75 mM each of
deoxyguanosine triphosphate, deoxythymidine triphosphate and
deoxycytidine triphosphate, 7.5 mM triphosphate deoxyadenosine
triphosphate, 1.5 mM magnesium, 1X PCR buffer, 2.5 mCi of
[35S]dATP 5 U ml21, and 0.5 U Taq. PCR was performed in a ther-
mocycler which can fit 96-microtiter plates (PTC-100–96V, MJ
Table 1 Clinical data of HCC patients
Case no. Sex Age HBsAg a-fetoprotein Anti-HCV Tumour Liver statea LOH Percentageb No. of instability
(mg ml21) diameter (cm)
1 F 55 N , 20 P 3.6 Cir 6.2 (11/178) 0
2 M 41 P , 20 N 7 Cir 9.3 (14/151) 0
3 M 59 P 139 N 2.6 Cir 1.3 (2/153) 1
4 F 67 N , 20 P 1.8 Cir 0 (0/164) 0
5 M 60 P 597 N 5 Cir 0.6 (1/168) 0
6 M 64 P , 20 ND 5 Cir 7.5 (12/161) 0
7 M 46 P 47 N 2.2 Cir 26.6 (42/158) 2
8 M 67 P , 20 N 3.6 CPH 10 (15/150) 1
9 M 39 P 25979 ND 8 Cir 6 (9/152) 0
10 M 29 P 21598 ND 4.3 Cir 4.7 (7/150) 0
11 F 43 P , 20 ND 4.5 Non-Cir 0 (0/164) 1
12 F 68 N 646 P 4.5 Cir 0 (0/171) 0
13 M 65 P , 20 P 2.2 Cir 3.2 (5/154) 0
14 F 57 N 47192 N 7.5 Cir 9.3 (16/172) 0
15 M 50 P , 20 N 2.5 Cir 0 (0/166) 0
16 M 44 P 237 ND 5 Cir 7.1 (11/155) 1
17 F 47 P , 20 N 5 CPH 16.8 (28/167) 0
18 F 64 N 497 P 3 Cir 3.4 (5/147) 0
19 M 31 P 190 N 4 Cir 10.4 (17/163) 0
20 M 56 P , 20 P 17 CPH 2 (3/151) 1
21 F 60 N , 20 P 4.8 Cir 0 (0/170) 2
22 M 60 N 37 P 2.5 Cir 0 (0/152) 0
23 M 60 P . 35000 N 20 CPH 0 (0/161) 0
24 M 63 N 905 P 2 Cir 0 (0/182) 0
25 M 63 N 23 P 3.2 Cir 0 (0/174) 0
26 F 65 P 1995 N 7 Cir 11.9 (18/151) 2
27 M 52 P 649 N 4 Non-Cir 0 (0/155) 0
28 M 54 P , 20 N 13 CPH 0 (0/162) 0
29 M 57 P , 20 N Ta 5 3 Cir 32.3 (53/164) 3
, 20 Tb 5 2 0.6 (1/165) 0
69.3 T1 5 2 9.7 (16/165) 0
69.3 T2 5 1.7 6.1 (10/165) 0
30 M 64 N , 20 P Ta 5 2.8 CPH 1.3 (2/154) 0
Tb 5 2.2 0 (0/153) 0
Ta, Tb: primary tumours; T1, T2: recurrent tumours; ND: not determined; F: female; M: male; N: negative; P: positive. a: Cir, cirrhosis; CPH, chronic persistent
hepatitis. b(no. of primers with LOH)(total no. of informative primers).470 J-C Sheu et al
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Research Inc., Watertown, MA, USA). Reactions were performed
in 27 cycles under the following conditions: 30 s at 948C for denat-
uration, 75 s at 558C for primer annealing and 30 s at 728C for
primer extension. Finally, PCR product was further incubated in
728C for another 6 min. The pipetting and dispensing of the PCR
reagents was performed by a Robotic workstation (Biomek 2000,
Beckman, Palo Alto, CA, USA). After completion of PCR, the
PCR products were run on a 6% polyacrylamide gel elec-
trophoresis (PAGE) gel followed by exposure of the gel to X-ray
film for 2–3 days. The band pattern between tumour and non-
tumour part was compared. The genetic changes, including LOH
and microsatellite instability, were analysed. The assessment of
LOH and microsatellite instability was done as described previ-
ously (Loeb, 1994; Yeh et al, 1994; Nagai et al, 1997)
Statistical analysis
We correlate LOH frequency with several clinical aspects,
including sex, age, tumour size, liver state, serum a-fetoprotein
(AFP) and status of hepatitis B or C virus infection. The statistical
analysis was performed by the computer program STATISTICA
(StatSoft, Tulsa, OK, USA). The P-values were obtained by
Fisher’s exact tests and the r-values were obtained by linear
regression analysis.
RESULTS
Study on LOH
We analysed 34 HCC samples and their corresponding non-tumour
DNA for LOH by microsatellite markers from chromosomes 1–22
and X chromosome. A total of 231 markers were used in this study.
The mean heterozygosity of the microsatellite markers was 70%.
The representative results of microsatellite amplifications in HCCs
are shown in Figure 1. In the DNA of non-tumour part that was
heterozygous at a locus, two alleles were amplified at similar effi-
ciency, and the resulting PCR product was separated on the gel as
two clustering bands of equivalent intensity. In contrast, in tumour
part with loss of one allele at this microsatellite locus, the gel
showed disappearance of clustering bands indicating LOH.
Frequency of LOH in each samples
Among the 34 HCC samples analysed, the frequency of LOH
(number of primers with LOH/number of informative primers)
ranged from 0% to 32.2% (average 5.5%) (Table 1). Except for
two HCC samples (case 7 and case 29 Ta) that had LOH frequency
of 32.3% and 26.6%, most of the HCC samples had LOH
frequency less than 10%. Of the 34 HCCs, 11 HCCs did not show
any LOH with the 231 markers tested.
In the four tumours of case 29, who had two tumours in two
operations, one tumour (Ta) had the highest LOH (53/164, 32.2%)
and the other three tumours had LOH less than 10%. In the two
tumours of case 30, who had two tumours, one tumour (Ta) had
two LOH locus, but the other tumour (Tb) had no LOH. The sites
of LOH in the four HCCs of the first case and the two HCCs of the
second case were all different.
Frequency of LOH in each chromosome
When the data were analysed based on the frequency of LOH in
each chromosome (allelic loss at one or more markers), the range
of LOH was from 0% to 47.1% (average 15.2%). There were six
chromosomes which had LOH more than 20%. The highest rate of
LOH were on chromosome 16 (16/34, 47.1%), followed by 5
(12/34, 35.3%), 13 (11/34, 32.4%), 17 (11/34, 32.4%), 9 (8/34,
26.5%) and 11 (8/34, 23.5%) (Table 3).
Frequency of LOH based on each microsatellite marker
The percentage of LOH on all microsatellite markers for 34 HCC
samples is shown in Table 2. The average frequency of LOH in each
microsatellite locus ranged from 0% to 50% (average 5.4%). Most of
the markers had LOH less than 20%, and only 12 markers had LOH
more than 20%. Among the 231 markers, the highest rates of LOH
were detected for specific loci on chromosome arm 9p21 (20.8%),
Table 2 Microsatellite markers used in this study and results of LOH at each locus in 34 HCCs
Chromosome
1 2 345678 9 1 01 1 1 2
D1S201 (0/23, 0%) D2S158 (0/23, 0%) D3S1307 (0/27, 0%) D4S419 (1/21, 4.8%) D5S406 (3/18, 16.7%) D6S296 (0/25, 0%) D7S511 (0/28, 0%) D8S265 (0/6, 0%) D9S168 (3/21, 14.3%) D10S223 (0/23, 0%) D11S932 (7/29, 24.1%) D12S93 (1/26, 3.8%)
D1S211 (0/24, 0%) D2S146 (0/34, 0%) D3S1297 (1/29, 3.4%) D4S396 (0/16, 0%) D5S395 (0/14, 0%) D6S289 (0/27, 0%) D7S493 (0/26, 0%) D8S282 (4/28, 14.3%) D9S162 (1/20, 5%) D10S197 (0/29, 0%) D11S921 (2/27, 7.4%) D12S89 (0/21, 0%)
D1S232 (0/25, 0%) D2S123 (0/23, 0%) D3S1304 (1/27, 3.7%) D4S416 (1/23, 4.3%) D5S426 (0/29, 0%) D6S306 (0/27, 0%) D7S485 (0/26, 0%) D8S278 (2/25, 8%) D9S169 (5/24, 20.8%) D10S218 (2/23, 8.7%) D11S915 (2/21, 9.5%) D12S87 (0/13, 0%)
D1S200 (0/27, 0%) D2S160 (1/27, 3.7%) D3S1263 (1/27, 3.7%) D4S410 (0/14, 0%) D5S420 (0/34, 0%) D6S272 (0/27, 0%) D7S499 (1/27, 3.7%) D8S260 (2/30, 6.7%) D9S165 (3/25, 12%) D10S206 (1/19, 5.3%) D11S914 (2/21, 9.5%) D12S96 (0/10, 0%)
D1S220 (0/32, 0%) D2S114 (1/27, 3.7%) D3S1266 (0/19, 0%) D4S406 (2/18, 11.1%) D5S427 (3/28, 10.7%) D6S313 (1/18, 5.6%) D7S502 (1/30, 3.3%) D8S271 (0/25, 0%) D9S197 (2/21, 9.5%) D10S215 (0/17, 0%) D11S905 (2/34, 5.9%) D12S104 (0/27, 0%)
D1S230 (0/26, 0%) D2S150 (1/24, 4.2%) D3S1260 (0/20, 0%) D4S427 (4/28, 14.3%) D5S428 (1/23, 4.3%) D6S284 (3/27, 11.1%) D7S524 (0/20, 0%) D8S269 (0/8, 0%) D9S177 (1/21, 4.8%) D10S192 (2/27, 7.4%) D11S937 (2/28, 7.1%) D12S92 (0/34, 0%)
D1S219 (0/26, 0%) D2S142 (1/26, 3.8%) D3S1313 (1/24, 4.2%) D4S417 (2/15, 13.3%) D5S421 (0/23, 0%) D6S283 (4/28, 14.3%) D7S501 (0/24, 0%) D8S284 (0/30, 0%) D9S179 (3/28, 10.7%) D10S217 (2/29, 6.9%) D11S938 (5/19, 26.3%) D12S106 (0/1, 0%)
D1S236 (1/23, 4.3%) D2S152 (1/26, 3.8%) D3S1261 (1/19, 5.3%) D4S621 (0/10, 0%) D5S393 (1/31, 3.2%) D6S266 (4/24, 16.7%) D7S522 (1/26, 3.8%) D11S934 (4/34, 11.8%) D12S81 (0/34, 0%)
D1S223 (0/15, 0%) D2S172 (0/27, 0%) D3S1290 (0/25, 0%) D4S415 (4/29, 13.8%) D5S413 (4/25, 16%) D6S303 (2/18, 11.1%) D7S487 (0/21, 0%) D12S101 (0/16, 0%)
D1S194 (0/15, 0%) D2S140 (1/30, 3.3%) D3S1279 (0/26, 0%) D5S410 (1/23, 4.3%) D6S304 (2/21, 9.5%) D7S500 (1/30, 3.3%) D12S78 (0/16, 0%)
D1S218 (0/25, 0%) D3S1275 (0/10, 0%) D5S412 (4/31, 12.9%) D6S262 (2/26, 7.7%) D7S483 (2/28, 7.1%)
D1S242 (0/27, 0%) D3S1262 (0/28, 0%) D5S423 (1/22, 4.5%) D6S308 (3/26, 11.5%)
D1S215 (0/24, 0%) D3S1288 (1/34, 2.9%) D5S400 (4/28, 14.3%) D6S314 (3/17, 17.6%)
D1S240 (0/19, 0%) D3S1272 (1/21, 4.8%) D5S425 (2/23, 8.7%) D6S311 (2/25, 8%)
D1S254 (0/12, 0%) D5S394 (0/22, 0%) D6S305 (2/23, 8.7%)
D1S191 (0/25, 0%)
D1S222 (0/25, 0%)
D1S238 (0/22, 0%)
D1S306 (1/26, 3.8%)
D1S249 (0/27, 0%)
D1S217 (0/24, 0%)
D1S237 (0/19, 0%)
D1S304 (0/16, 0%)
D1S204 (0/17, 0%)
()%: indicates LOH cases/informative cases, LOH frequency. Xa: informative cases are few on X chromosome.Loss of heterozygosity and microsatellite instability in HCC 471
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11p15 (26.3%), 11q23–24 (24.1%), 13q12.1–12.2 (25%), 13q14.3
(20.6%), 13q21–32 (31.3%), 16q12.1 (31.6), 16q12.2 (50%), 16q13
(33.3%), 16q24 (30.4–33.3%) and 17p13 (39.3%) (Table 4). The
most frequent LOH was detected at locus D16S419 in 16q12.2 with
a frequency of 50% of 14 informative HCCs in our study.
Deletion mapping of chromosomes with frequent LOH
Deletion mapping by LOH analysis was performed on six chromo-
somes which had LOH frequency more than 20%. Deletion
mapping of chromosome 16 is shown in Figure 2A. Most of the 16
tumours that had LOH span the q arm (16/34, 47.1%). By further
mapping, the LOH regions were limited to three smaller regions.
The first region was near marker D16S409, the second was near
marker D16S419 and the third region is between markers
D16S402 and 16S408. The locations of D16S409 and 16S419
were on chromosome 16q12.1 and 16q12.2, while the locations of
D16S402 and D16S408 were on chromosome 16q24 and 16q13.
From the LOH mapping of tumours 18, 19, 25 and 19, the third
region was narrowed down to D16S422 (16q24). Therefore, the
minimal LOH regions commonly affected in these patients were
deduced to be 16q12.1, 16q12.2 and 16q24.
The deletion mapping of chromosome 13 is shown in Figure 2B.
In most affected samples, the LOH regions cover 13q (11/34,
32.4%). Furthermore, we found a smaller region of LOH between
D13S171 and D13S156. The locations of these markers were on
chromosome 13q12.1 and 13q32.
For chromosome 17, the LOH region seemed to span the p arm
(11/34, 32.4%) (Figure 2C). The minimal LOH region frequently
affected in these 11 patients was deduced to be around marker
D17S796. The localization of marker D17S796 was 17p13.
Similar analysis was performed on chromosomes 11, 9 and 5
(data not shown). Regions of LOH appear to cover both p arms of
chromosome 11 (8/34, 23.5% for the p arms; 5/34, 15% for the q
arms). In the p arm, the LOH region was near marker D11S932,
while the q arm was between D11S938 and D11S934. The loca-
tions of D11S932 and D11S934 were on chromosome 11p15 and
TN T
Figure 1 A representative result of LOH in HCC. DNA from one pair of liver
cancer (lane T) and non-tumour part (lane NT) was amplified by PCR with
microsatellite primer D13S155. Tumour DNA showed a disappearance of one
allele at this microsatellite loci
13 14 15 16 17 18 19 20 21 22 Xa
D13S221 (1/15, 6.7%) D14S72 (1/29, 3.4%) D15S128 (3/30, 10%) D16S418 (4/31, 12.9%) D17S796 (11/28, 39.3%) D18S59 (0/23, 0%) D19S209 (3/23, 13%) D20S113 (1/26, 3.8%) D22S265 (0/28, 0%) D22S280 (2/29, 6.9%) DXS987 (0/7, 0%)
D13S171 (5/20, 25%) D14S70 (0/29, 0%) D15S165 (2/15, 13.3%) D16S406 (2/30, 6.7%) D17S786 (3/18, 16.7%) D18S63 (0/29, 0%) D19S221 (0/13, 0%) D20S115 (0/18, 0%) D21S269 (0/22, 0%) D22S281 (2/25, 8%) DXS989 (1/8, 12.5%)
D13S218 (2/24, 8.3%) D14S75 (1/26, 3.8%) D15S123 (1/30, 3.3%) D16S414 (1/26, 3.8%) D17S783 (1/17, 5.9%) D18S62 (0/19, 0%) D19S213 (0/25, 0%) D20S104 (0/34, 0%) D22S262 (1/29, 3.4%) D22S278 (1/34, 2.9%) DXS991 (0/7, 0%)
D13S155 (5/27, 18.5%) D14S66 (1/24, 4.2%) D15S119 (0/34, 0%) D16S410 (2/18, 11.1%) D17S805 (0/17, 0%) D18S71 (0/27, 0%) D19S220 (0/16, 0%) D20S118 (0/34, 0%) D21S261 (1/22, 4.5%) D22S277 (2/34, 5.9%) DXS1000 (0/4, 0%)
D13S153 (7/34, 20.6%) D14S61 (1/24, 4.2%) D15S125 (1/34, 2.9%) D16S417 (1/19, 5.3%) D17S791 (0/27, 0%) D18S65 (1/28, 3.6%) D19S223 (0/25, 0%) D20S112 (0/34, 0%) D21S270 (2/23, 8.7%) D22S283 (1/33,3%) DXS995 (1/9, 11.1%)
D13S176 (3/26, 11.5%) D14S68 (2/23, 8.7%) D15S127 (1/34, 2.9%) D16S409 (6/19, 31.6%) D17S788 (1/24, 4.2%) D18S69 (1/32, 3.1%) D19S217 (0/24, 0%) D20S106 (0/25, 0%) D21S267 (2/24, 8.3%) D22S279 (1/34, 2.9%) DXS990 (0/6, 0%)
D13S156 (5/16, 31.3%) D14S81 (3/23, 13%) D16S416 (2/18, 11.1%) D17S792 (0/24, 0%) D18S60 (0/19, 0%) D19S214 (0/26, 0%) D20S120 (0/13, 0%) D21S266 (2/33, 6.1%) D22S276 (0/16, 0%) DX984 (0/1, 0%)
D13S157 (2/20, 10%) D14S78 (2/32, 6.3%) D16S419 (7/14, 50%) D17S789 (1/14, 7.1%) D18S68 (1/29, 3.4%) D19S218 (0/28, 0%) D20S100 (0/18, 0%) D22S282 (1/15, 6.7%)
D13S159 (4/19, 21.1%) D16S415 (4/25, 16%) D17S784 (1/23, 4.3%) D18S58 (3/28, 10.7%) D20S102 (0/34, 0%) D22S274 (0/33, 0%)
D13S173 (1/30, 3.3%) D16S408 (6/18, 33.3%)
D16S422 (8/24, 33.3)
D16S402 (7/23, 30.4%)472 J-C Sheu et al
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11q23–q24 respectively. For chromosome 9, the LOH regions
spanned the whole 9p arm (7/34, 20.6%). One smaller LOH region
was mapped to chromosome 9p21 (D9S169). For chromsome 5,
we found that these LOH regions spanned the chromosome 5q
arm (9/34, 26.5%). Three distinct regions, D5S413(5q32),
D5S412(5q34) and D5S400(5q35.2), were mapped.
Correlation analysis based on HCC samples and LOH
We correlated the LOH frequency of each HCC sample with the
clinical status. There was no significant correlation with sex, age,
status of HCV antibody, AFP or liver status. However, among the
34 HCC samples, tumours in those patients positive for HBsAg
tended to have higher frequency of LOH (primers with LOH/
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 10 11 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
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Figure 2 Summary of the results of LOH analysis on chromosomes that have LOH frequency more than 15% in 34 HCCs. The locations of the microsatellite
markers are shown. The patients are indicated by the number shown at the top of the Figure; case 29: tumours 29–32, case 30: tumours 33–34. Non-
informative indicated no polymorphism between alleles at the markers. Therefore, no LOH information could be obtained. •, Informative with two alleles 
normally intact (l); LOH (l l); non-informative (no allelic polymorphism) (n n). (A) Chromosome 16, (B) chromosome 13, (C) chromosome 17Loss of heterozygosity and microsatellite instability in HCC 473
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informative primers) (Table 1), but the difference was not statisti-
cally significant (P . 0.05)
Correlation analysis based on each chromosome and LOH
After analysing several clinical aspects, including sex, age, AFP
and status of HCV infection, no significant correlation between
these parameters and LOH frequency for each chromosome was
found. Interestingly, we found significant correlation between
LOH on chromosome 5q, 11p, 16q and positivity of HBsAg.
For the 34 randomly selected HCCs, LOH on chromosome 5q
was found in nine of 23 (39.1%) HCCs who were positive for
HBsAg, but none in 11 (0%) HCCs who were HBsAg-negative. A
significant difference between these two groups was observed
(P , 0.05). At the same time, LOH on chromosome 11p was
found more frequently in HBV-positive than in HBV-negative
HCCs (8/23, 34.7% vs 0/11, 0%; P , 0.05). Similarly, a signifi-
cant correlation between hepatitis B virus carrier and LOH on
chromosome 16q was also found (14/23, 60.7% vs 2/11, 18%;
P , 0.05).
Correlation analysis based on each locus and LOH
After analysing the clinical parameters with the LOH frequency
that were greater than 20% in 13 microsatellite loci, we found the
larger tumour size tended to have higher frequency of LOH at
D16S409 (r 5 0.59136, P 5 0.0097). However, there was no
significant correlation between the LOH frequency of the
remaining 12 microsatellite loci and clinical parameters.
Study on microsatellite instability
The mobility shift in tumour DNA compared to corresponding
normal DNA samples representing microsatellite instability is
shown in Figure 3. Except for nine HCC samples which had few
numbers of instability (Table 1), most of the HCCs had no band
shift on gel electrophoresis. Microsatellite instability was found in
12 of 231 markers: D1S219, D1S249, D4S406, D5S413, D7S502,
D11S914, D13S155, D13S176, D19S217, D19S214, DX989 and
DX990. Only one patient had instability on the marker for each
locus respectively. Of the 12 markers which had microsatellite
instability, ten showed an increasing number of repetitive
sequences, the remaining two showed a decreasing number of
repetitive sequences.
Table 3 Summary results of LOH analysis in each chromosome in 34 HCC tumours
Chromosome no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X
No. of tumour with 1 4 2 6 12 4 4 6 9 2 8 1 11 5 3 16 11 3 3 1 2 3 2
LOH (allelic loss at
one more markers)
Frequency of 2.9 11.8 5.9 17.6 35.3 11.8 11.8 17.6 26.5 5.9 23.5 2.9 32.4 14.7 8.8 47.1 32.4 8.8 8.8 2.9 5.9 8.8 5.9
LOH (%)
TN T
Figure 3 A result of microsatellite instability in HCC. DNA from one pair of
liver cancer (lane T) and non-tumour part (lane NT) was amplified by PCR
with microsatellite primers D19S214. Arrows show increasing or decreasing
number of repeats
Table 4 Summary of microsatellite marker loci demonstrating significant
frequency of LOH in HCC
Chromosomal locations Locus LOH frequency
LOH/informative cases (%)
9p21 D9S169 5/24 20.8
11p15 D11S932 7/29 26.3
11q23–24 D11S938 5/19 24.1
13q12.1–q12.2 D13S171 5/20 25.0
13q14.3 D13S153 7/34 20.6
13q21–q32 D13S156 5/16 31.3
16q12.1 D16S409 6/19 31.6
16q12.2 D16S419 7/14 50.0
16q13 D16S408 6/18 33.3
16q24 D16S422 8/24 33.3
D16S402 7/23 30.4
17p13 D17S796 11/28 39.3474 J-C Sheu et al
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DISCUSSION
Recently, microsatellite polymorphism studies have determined
frequent LOH on chromosomes 1p, 1q, 2q, 4q, 5q, 6q, 8p, 8q, 9p,
9q, 10q, 11p, 13q, 14q, 16p, 16q, 17p, 17q and 22q in HCCs
(Buetow et al, 1989; Tsuda et al, 1990; Konishi et al, 1993; Nose et
al, 1993; Takahashi et al, 1993; Fujimoto et al, 1994; Fujiwara et
al, 1994; Yeh et al, 1994; Kuroki et al, 1995a 1995b; Yumoto et al,
1995; Nagai et al, 1997). In agreement with their data, we demon-
strated frequent LOH on chromosomes 5q, 9p, 11p, 13q, 16q and
17p in this study. In addition, we found a new location exhibiting a
high rate of LOH on chromosome 11q23–24 (24.1%). Therefore,
chromosome 11q23–24 might be a new location of tumour
suppressor gene. Our study did not find frequent LOH on chromo-
some arms 1p, 1q, 2q, 4q, 8p, 8q, 9q, 14q, 16p, 17q and 22q as
reported by previous investigators. The most likely possibility of
the difference is that the tumour size in our study is smaller than in
previous investigations. The larger tumours might have obtained
more secondary genetic changes during tumour development.
However, the use of different microsatellite markers might be
another possibility of this discrepancy.
Yeh et al (1994) reported LOH (30%) on chromosome 1p in
HCC in Taiwan and mapped a commonly affected LOH region to
1p35–36. However, all the tumours used in their study were larger
than 5 cm. Comprehensive allelotyping analysis by Nagai et al
(1997) found frequent LOH on chromosome 1p and 1q in small
HCCs. In the present study, a total of 24 microsatellite markers
were used for chromosome 1, but our data showed only 3.3% LOH
on chromosome 1.
In this study, we showed that chromosome 16q had the highest
LOH frequency among all the chromosomes studied and the
common LOH regions were mapped to 16q12.1, 16q12.2 and
16q24, which are different from 16q22–23 reported by Yeh et al
(1996) and 16q23–24 reported by Nagai et al (1997). E-cadherin
gene, which was located at chromosome 16q22, has been reported
to play important role in tumour progression in a variety of human
cancers including HCC (Slagle et al, 1993) and might be a tumour
suppressor gene in this region. However, our data suggest that
alterations occur in two different loci on 16q; this has not been
reported in previous investigations. Because chromosome 16q
contains many other important genes, such as phosphorylase
kinase b (PHKb, 16q12.1), retinoblastoma-related human gene
(RB2, 16q12.2), collagenase (MMP2, 16q13), cytochrome c
oxidase subunit IV (COX4, 16q24.1), adenine phosphoribosyl
transferase (APRT, 16q24.2), N-acetylgalactosamine-6-sulphatase
(GALNS, 16q24.2) and cellular adhesion regulatory molecule
(CARM, 16q24.3), the deletion of this region may interfere with
cell growth or function (Buetow et al, 1989; Tsuda et al, 1990;
Slagle et al, 1993; Yeung et al, 1993; Kamatani, 1996). Therefore,
it is likely that the two new loci detected in our study may contain
important tumour suppressor genes.
As in our study, previous investigators (Kuroki et al, 1995b)
found a high rate of LOH on 13q and mapped the common regions
to 13q12.1–q32, which harbours the Rb and BRCA2 tumour
suppressor genes (Hada et al, 1996). The role of these two genes in
HCC needs to be established. Meanwhile, frequent LOH on chro-
mosome 17p13 was also detected. The tumour suppressor gene,
p53, located around chromosome 17p13 has been reported to be
mutated frequently in a variety of human cancers including HCC
(Hsu et al, 1994; Yumoto et al, 1995). In this region, p53 might be
the target gene and play an important role in the development of
HCC. As for chromosome 11, we mapped the minimal LOH
region to 11p15 and 11q23–q24. Wang and Royler (1988) have
mapped the fine LOH region to 11p13 in HCC, which was
different from our data. The significance of these two new loci on
chromosome 11 needs further study. Recently, the p16/MTS1 and
P15/MTS2 genes, located at chromosome 9p21–22, were found to
be important tumour suppressor genes in human cancers (Kamb et
al, 1994; Linardopoulos et al, 1995). In this study, we found the
LOH frequency was 14.7% at marker D9S169 on chromosome
9p21 in HCC. In addition, we found that the frequency of p15 gene
alteration is about 14% in HCC (Lin et al, 1998). However, the
frequency of p16 gene alteration is very rare (3%) in HCC in our
studies (Lin et al, 1998) and in a previous report (Kita et al, 1996).
These results suggested that p15 might be the tumour suppressor
gene on 9p21 in HCC. However, the possibility of the presence of
other tumour suppressor genes cannot be excluded.
Early studies have demonstrated high frequency of LOH on
chromosome 4q in HCC (Yeh et al, 1996; Fujimoto et al, 1994).
Because chromosome 4q contains genes encoding albumin,
alcohol dehydrogenase (ADH3), fibrinogen and UDP-glucuronyl-
transferase, which are expressed predominantly in the liver, the
LOH of this region may interfere the liver function (Buetow et al,
1989). Therefore, chromosomal alterations in this region seem to
be an unique trait in HCC (Nagai et al, 1997). By microsatellite
analysis, LOH on 4q has been mapped to 4q11–q12, 4q12–23,
4q22–24 and 4q35 (Buetow et al, 1989; Yeh et al, 1996; Nagai et
al, 1997). However, our data showed lower LOH (14.3%) than
previous data, in wider locus of 4q21–28 in HCC. Recently, Nagai
et al (1997) reported that 42% of their HCCs had LOH on 8p23
(8S277) and argued that a tumour suppressor gene for HCC lies in
this region. A candidate tumour suppressor gene, the PRLTS gene
located on 8p21–22, has been found to be mutated in sporadic
colorectal carcinoma and HCCs (Fujiwara et al, 1995). On the
other hand, we also found LOH on 8p21.3 (D8S282) in only
14.3% of our HCCs. These differences might be due to different
race, different tumour stages and different markers. However,
further elucidation of the discrepancy is necessary.
As for chromosome 6, a candidate tumour suppressor gene, the
M6P/IGF2R gene, which was mapped to 6q26–27, was found to
have LOH in 70% of HCC (De Souza et al, 1995a). Recently, De
Souza et al (1995b) showed that the M6P/IGF2R gene was deleted
and mutated in HCCs with LOH. In our study, we only found LOH
in 17.6% of our HCCs on 6q16.3–27 (D6S314), which includes
the locus 6q26–27. The cause of this discrepancy needs further
investigation. However, it is probable that the LOH in our series
might be underestimated; recently, Yamada et al (1997) have
shown that hepatocytes adjacent to HCCs that appear normal
might already have LOH. The only way to elucidate the difference
is to use blood or some other non-liver normal tissue for deter-
mining whether a person is informative at loci on 6q. This experi-
ment is now ongoing in our lab.
HBV infection has been regarded as an important factor in the
development of HCC (Beasley, 1982; Chen, 1987). However, the
molecular mechanism is unclear. In this study we found the LOH
frequency in HBsAg-positive HCC patients was significantly higher
on chromosome 5q, 11p and 16q than those who are negative for
HBsAg. These data imply that HBV infection might cause genetic
changes within chromosomal regions where this is important for the
development of some HCCs. Using RFLP, Wang and Rogler (1988)
have demonstrated that allelic loss in 11p and 13q occurs in a higher
percentage of HCCs arising from HBV carriers. Recently, Beckerand Zhou (1996) have shown frequent loss of chromosome 8p in
HBV-positive HCC from China. The discrepancy needs further
study. By linear regression, the LOH frequency of D16S409
(16q12.1) has a positive relation with tumour size. Previous investi-
gation has reported that the high frequency of LOH on chromosome
16q arm is usually accompanied with advanced stage of HCC
(Tsuda et al, 1990). Our data suggest that a tumour suppressor gene
near D16S409 (16q12.1) might be involved in the progression of
HCC. In addition to HBsAg and tumour size, we found no correla-
tion between LOH frequency and clinical parameters, including sex,
AFP, age, liver state and anti-HCV.
To study the role of microsatellite instability in liver carcino-
genesis, we screened 34 HCCs at 231 microsatellite loci on 22 auto-
somal chromosomes and X chromosome. Although microsatellite
instability is significant in HNPCC and other cancers (Peinado et al,
1992; Gonzalez-Zulueta et al, 1993; Han et al, 1993; Ionov et al,
1993; Peltomaki et al, 1993; Risinger et al, 1993; Thibodeau et al,
1993; Loeb, 1994; Merlo et al, 1994), in our study, microsatellite
instability was only found in 12 of 231 markers. More recently,
Kazachokov et al (1998) and Macdonald et al (1998) have shown
that microsatellite instability occurs in approximately 35% of
HCCs. The discrepancy in microsatellite instability between our
HCCs and their HCCs might reflect the difference in the tumour
size (smaller in our series) and the fact that the number of markers
we used was more extensive. However, other factors such as
different geographic area and different criteria for microsatellite
instability might contribute to the difference.
In this study, one patient (case 29) had multiple and recurrent
tumours, and the other patient (case 30) had multiple tumours.
After analysing the six multiple small HCCs, we found all the
tumours had different sites of LOH. Although the case number is
limited, these data further support our previous observations that
multiple small HCCs usually arise from different clonality (Sheu
et al, 1993).
In summary, we have used microsatellite polymorphism
analysis to screen LOH frequency of every chromosome in HCC,
and the results provide a basal information for further positional
cloning of putative tumour suppressor genes. Further fine mapping
of LOH on chromosome arms that have a higher frequency of
LOH, and cloning of the candidate genes in these areas, is ongoing
in our lab.
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